Healthcare Professional

CG Oncology is committed to advancing science through clinical trials. Our lead candidate, cretostimogene grenadenorepvec, is an oncolytic immunotherapy with a dual mechanism of action.

Learn more about CG Oncology’s ongoing Clinical Trials

Healthcare Professional

CG Oncology is committed to advancing science through clinical trials. Our lead candidate, cretostimogene grenadenorepvec is an oncolytic immunotherapy with a dual mechanism of action.

Learn More

Videos

Slide Two

Please watch these videos to learn more or share this Mechanism of Action video with your patients

Why Clinical Trials:

It’s important for patients to know, when designing these studies, that there is input from a wide variety of physicians, patients and regulatory bodies. Even at each institutional level [clinical trials] go through a really high degree of scrutiny to protect patients.

Sima P. Porten MD, MPH

Assistant Professor, Urology, University of California, San Francisco

Discover how CG Oncology is championing diversity and equity in our clinical trials.

Learn More

Clinical Trials

Learn how CG Oncology is committed to diversity in our clinical trials.

Learn More

Resources

Download our resources to learn more about our work in developing a bladder-sparing therapeutic option for those affected by bladder cancer.

Learn More

Contact Us

For more information about our clinical trials, feel free to contact our team.

Learn More